Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase EARLY_PHASE1 1Phase 1 1

Status

Not yet recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 31Thoracic 26Head & Neck 10Dermatologic 9Breast 5Gynecologic 4Genitourinary 4Tumor-Agnostic 2Lymphoid 2CNS 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Neoplasm, Residual 1HER2-Negative Locally Advanced Breast Cancer 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Immunotherapy × Breast × Clear all
NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
119 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT07254858 2025-11-28

CISN-L

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting
302 enrolled
Breast

Breast Neoplasms

NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

NCT06691594 2025-02-20

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02539017 2016-08-10

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡